How do immune cells strike a balance, unleashing rapid attacks against pathogens or cancer, while avoiding damage to healthy cells? Research into an immune kill switch holds potential for controlling ...

– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester ...

Bracco Imaging and Limula, a life science tools company specializing in automated cell and gene therapy manufacturing solutions, launched a R&D project in collaboration with Nicola Vannini, PhD, who ...

Aurigene Oncology Ltd. recently provided details on the discovery and preclinical characterization of AUR-243, a novel CBL-B inhibitor with a distinct therapeutic profile and best-in-class potential ...

Infusions of platelet factor 4 (PF4) have reversed aging in human hematopoietic stem cells (HSCs), the precursors of a range of blood and immune cells. A team from the University of Illinois Chicago ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A new startup in Chapel Hill is ...

Metabolism guides the activation states of regulatory T cells, the immune cells that prevent inappropriate activation of the immune system. St. Jude Children's Research Hospital scientists recently ...

Regeneron has given up on a CAR-T candidate acquired from 2seventy bio last year, before it entered the second part of a phase 1/2 lymphoma study. The dual-targeting CAR-T, dubbed bbT369, was being ...

Findings establish CAR-M as a potential new immune-reset modality with improved safety over in vivo CAR-T approaches CAMBRIDGE, Mass.--(BUSINESS WIRE)--Liberate Bio, Inc., a biotechnology company ...